Cancer medicines
Atezolizumab
Atezolizumab
An immune checkpoint inhibitor targeting PD-L1.
Sources checked · Introductory guide
On this page
How it works
It blocks PD-L1-related immune suppression, helping immune cells attack cancer.[1]
Where it is used
Used alone or with other medicines in selected lung cancers, hepatocellular carcinoma and other settings.[1]
Key safety points
Report new cough, breathing difficulty, diarrhea or jaundice immediately, as well as chills or dizziness during infusion.[2]
Questions for your care team
- Which possible immune-related symptoms require prompt contact?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.